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Background: Despite the serious consequences of rubella infection during early pregnancy, very little is known
about the rubella seroprevalence in a number of African countries including Burkina Faso.
Methods: Between December 2007 and March 2008 serum samples were collected from 341 pregnant women in
Bobo (n = 132, urban area) and Houndé (n = 209, rural area) and were tested for rubella-specific IgG antibodies with
a commercial ELISA kit.
Results: An overall seropositivity rate of 95.0% (324/341) was found, with a higher percentage in the urban
population and in the oldest age group. Considering an antibody titer of at least 10 International Units per ml as
protective, the overall immunity rate in the cohort of pregnant women was 93.3% (318/341).
Conclusions: The high overall seropositivity rate in the absence of routine immunization suggests a continuous
transmission of endemic rubella virus in Burkina Faso, posing a threat to non-immune pregnant women.
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Rubella is normally a self-limiting febrile illness without
significant long term morbidity [1]. Infection during
pregnancy, however, may lead to miscarriage, fetal death
or the birth of an infant with congenital rubella syn-
drome (CRS) [2]. It is estimated that worldwide more
than 100 000 children with CRS are born each year [3].
Although the rubella seroprevalence among women in
child-bearing age has been studied in several African
countries [4-9], only one report from the Upper Volta
region in Burkina Faso dating back to 1982 [10] and a
recent study comprising only 100 women from a single
location [11] are currently available to estimate the CRS
risk in this country. Rubella vaccination is not included
in the national immunization schedule in Burkina Faso
and only few doses of vaccine are applied in the private
sector. The aim of this study was to determine how
many pregnant women are at risk of primary infection* Correspondence: claude.muller@crp-sante.lu
2Institute of Immunology, Centre de Recherche Public de la Santé/
Laboratoire National de Santé, 20A rue Auguste Lumière, Luxembourg, L
1950, Luxembourg
Full list of author information is available at the end of the article
© 2013 Tahita et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwith rubella in a rural and urban area in the region of
Bobo-Dioulasso, Burkina Faso.Methods
Venous blood samples were collected between December
2007 and March 2008 from 341 pregnant women in
health centers in Bobo (n = 132, urban area) and Houndé
(n = 209, rural area). The women’s age ranged from 16 to
42 years (mean: 25.7 ± 5.8 years), with more than half
(58.9%) of them being 20–29 years old (Table 1). Informed
consent to participate in the study was obtained from all
women and a questionnaire comprising data on educa-
tional, marital, and pregnancy status, monthly income and
history of previous exanthematous diseases was completed
for each participant. All samples were transported to the
laboratory on the day of collection for serum extraction
and subsequent storage at -20°C.
The serum samples were screened manually for rubella-
specific IgG antibodies using a commercial ELISA test
(Enzygnost Anti-Rubella-Virus/IgG, Siemens, Germany).
All equivocal samples were retested and if the result was
confirmed, the sample was classified as equivocal, otherwise
as positive or negative.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Rubella IgG ELISA results in relation to age and place of residence
Age groups (in years) Place of residence
16-19 20-29 30-39 40-42 Bobo Houndé
No. of positives 51 (92.7%; 95% CI
85.7-99.7%)
194 (96.5%; 95% CI
94.0-99.1%)
73 (92.4%; 95% CI
86.5-98.3%)
6 (100%) 126 (95.5%; 95% CI
91.9-99.0%)
198 (94.7%; 95% CI
91.7-97.8%)
No. of positives
with ≥ 10 IU/ml
49 (89.1%; 95% CI
80.7-97.4%)
192 (95.5%; 95% CI
92.6-98.4%)
71 (89.9%; 95% CI
83.2-96.6%)
6 (100%) 125 (94.7%; 95% CI
90.8-98.5%)
193 (92.3%; 95% CI
88.7-96.0%)
No. of negatives 4 7 5 0 6 10
No. of equivocals 0 0 1 0 0 1
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package for social science software (SPSS, version 15,
Chicago Incorporation), Data Analysis and Statistical
Software (Stata, version 10, StataCorp LP, Texas, USA)
and Microsoft Office Excel 2004. Tests of significance
were conducted using the chi-square test at a significance
level of 0.05. The study protocol was approved by the
Institutional Ethics Committee of Centre Muraz.
Results
All but 17 of the 341 pregnant women tested were rubella
IgG positive, which corresponds to an overall seropositivity
rate of 95.0% (95% CI 92.0-99.4%). Seropositivity was lowest
among the 30–39 and the 16–19 year old women and
highest among the 40–42 year olds (92.4%; 95% CI 86.5 –
98.3% and 92.7%; 95% CI 85.7-99.7% versus 100.0%)
(Table 1). The seropositivity rate was higher among women
from the urban than the rural community (95.5%; 95% CI
91.9-99.0% versus 94.7%; 95% CI 91.7-97.8%, p > 0.05).
There were no statistically significant correlations between
rates of rubella seropositivity and educational, marital, and
pregnancy status, monthly income or history of previous
exanthematous diseases.
Of the 324 seropositive women, 318 (193 or 97.5%; 95%
CI 96.0-99.5% from the rural setting and 125 or 99.2%; 95%
CI 98.2-99.8% from the urban area) had antibody titers of
at least 10 International Units (IU) per ml and were thus
considered protected against rubella infection [12], while
the remaining 6 women are potentially at risk of reinfec-
tion. The overall immunity rate in the cohort of pregnant
women was 93.3% (318/341, 95% CI 90.3-96.3%) with a
higher percentage of immune women in the urban setting
than in the rural area (94.7%; 95% CI 90.8-98.5% versus
92.3%; 95% CI 88.7-96.0%, p = 0.1) and in the oldest as
compared to the youngest women (100% versus 89.1%; 95%
CI 80.7-97.4%, p = 0.6) (Table 1).
Discussion
This study provides for the first time rubella seroprevalence
data for an urban and a rural setting in the western part of
Burkina Faso. Though the study is limited to 341 pregnant
women from two locations, the high overall immunity rate
suggests a well-supported and continuous transmission ofendemic rubella virus in the country. As a result most
women become infected before reaching childbearing age.
Nevertheless, the number of protected women continues to
increase from 89.1% below the age of 20 to more than 95%
in the 20–29 year olds, the age at which nearly 60% of the
women gave birth. Beyond the age of 40 all women have
antibodies against rubella. Since rubella vaccine is rarely
given to adults in Burkina, our results suggest that a sizable
number of women become infected during child-bearing
age. In a previous report from Ouagadougou in central
Burkina, an overall seroprevalence of 77% was found
among pregnant women and the seropositivity rates
seemed to decrease with age from 85% in the 18–25 year
olds to 65% in the 36–50 year olds [11]. Nevertheless, the
overall results indicate that a considerable proportion of
pregnant women in Burkina are at risk of primary infection
with rubella virus. In Burkina vaccination against rubella is
provided by the private sector to a limited number of
children. This low-coverage immunization may lead to a
reduced circulation of rubella virus followed by a higher
age of first exposure and therefore increased risk of CRS
[13]. Based on the overall immunity rate found in this study
and an estimated birth rate for Burkina Faso of 43.2 births/
1000 population [14], we calculated that per year about
50000 pregnant women are at risk of rubella infection.
Without any information on rubella incidence in Burkina
Faso, reliable estimates of CRS case numbers are impos-
sible, but considering that up to 90% of primary infections
during the first 8–10 weeks of gestation may lead to fetal
defects [12], the number of CRS cases is potentially quite
high. Prevention of CRS is the main aim of rubella vaccin-
ation. Thus a rubella vaccination strategy in Burkina needs
to ensure high enough vaccination coverage rates (≥ 80%)
to interrupt indigenous virus circulation [12]. If this cannot
be assured in a sustainable way the number of CRS cases
may even further increase [13]. Similarly, vaccination in the
private sector which does not reach high enough coverage
can lead to more CRS cases [15].
Conclusions
In conclusion, this study presents for the first time rubella
seroprevalence data for an urban and a rural setting in
the western part of Burkina Faso and although the study
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seropositivity in the absence of routine vaccination
suggests a continuous transmission of endemic rubella virus
in Burkina Faso. While most women acquire seropositivity
before reaching childbearing age, the virus represents a
considerable threat to non-immune pregnant women.
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